Clinical Trial

Ravulizumab Outcomes in Polish Patients With aHUS

Study acronym: aHUS-OPTIMUM
Recruiting
View on ClinicalTrials.gov →
Summary
This multicenter, observational cohort study uses retrospective collection of past medical history and prospective follow-up to capture longitudinal data on the management and clinical outcomes of patients with atypical hemolytic uremic syndrome (aHUS) treated with ravulizumab as part of routine clinical practice under Poland's National Drug Program (NDP).
Protocol Amendment History 2 changes
critical Recruitment opened 2026-07-08
notable Trial sites expanded: 0 -> 10 locations 2026-07-08
Trial Details
NCT Number NCT07399730
Lead Sponsor AstraZeneca
Conditions Atypical Hemolytic Uremic Syndrome
Enrollment 80 participants
Start Date 2026-06-24
Primary Completion 2030-12-31 (estimated)
Study Completion 2030-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-07